When.com Web Search

  1. Ads

    related to: is evenity a bisphosphonate drug

Search results

  1. Results From The WOW.Com Content Network
  2. Romosozumab - Wikipedia

    en.wikipedia.org/wiki/Romosozumab

    Romosozumab, sold under the brand name Evenity (/ ɪ ˈ v ɛ n ɪ t i / ih-VENN-ih-tee or with the pin-pen merger, / ɪ ˈ v ɪ n ɪ t i / ih-VINN-ih-tee), is a medication used to treat osteoporosis. [ 7 ] [ 8 ] It has been found to decrease the risk of fractures of the spine .

  3. Bisphosphonate - Wikipedia

    en.wikipedia.org/wiki/Bisphosphonate

    Bisphosphonates are used to treat osteoporosis, osteitis deformans (Paget's disease of the bone), bone metastasis (with or without hypercalcemia), multiple myeloma, and other conditions involving fragile, breakable bone. In osteoporosis and Paget's, the most popular first-line bisphosphonate drugs are alendronate and risedronate.

  4. Phosphonate - Wikipedia

    en.wikipedia.org/wiki/Phosphonate

    Bisphosphonates are popular drugs for treatment of osteoporosis. [1] Clodronic acid is a bisphosphonate used as a drug to treat osteoporosis. In biochemistry and medicinal chemistry, phosphonate groups are used as stable bioisosteres for phosphate, such as in the antiviral nucleotide analog, Tenofovir, one of the cornerstones of anti-HIV therapy.

  5. Amgen's (AMGN) Osteoporosis Drug Evenity Gets FDA Approval - AOL

    www.aol.com/news/amgens-amgn-osteoporosis-drug...

    For premium support please call: 800-290-4726 more ways to reach us

  6. Amgen's Osteoporosis Drug Evenity Gets Approval in Europe - AOL

    www.aol.com/news/amgens-osteoporosis-drug...

    The EC grants marketing authorization to Amgen (AMGN) and partner UCB's Evenity for the treatment of severe osteoporosis in postmenopausal women at high risk of fracture.

  7. Amgen's Osteoporosis Drug Evenity Gets Adverse CHMP View - AOL

    www.aol.com/news/amgens-osteoporosis-drug...

    The CHMP provides an unfavorable feedback to Amgen's (AMGN) marketing application for Evenity to treat severe osteoporosis in postmenopausal women with risk of fracture.